New drug may prevent chemotherapy-induced nerve damage

 Researchers have successfully tested a new molecule that is capable of preventing the development of a nerve damaging condition caused by chemotherapytreatment in cancer patients.

Chemotherapy-induced peripheral neuropathy is the most prevalent neurological complication of anti-cancer treatment and a common dose-limiting side effect.

An estimated 30 per cent to 40 per cent of cancer patients who receive chemotherapy experience the neurological complication, characterised by tingling, numbness, weakness and pain from nerve damage, usually in the hands and feet.

This causes a negative impact on the quality of life of the patient, and leads to dose reduction or discontinuation of chemotherapy, with the potential decrease of survival chances that entails.

However, the new molecule was found to prevent the onset of this adverse effect, said researchers from the Bellvitge University Hospital in Spain.

The findings, of the clinical trial detailed in the journal Neurotherapeutics, showed that individuals who took the new drug demonstrated a decrease in the appearance of disorders associated with nerve dysfunction.

"The Phase 2b clinical trial (randomised with placebo) has allowed us to get a great deal of scientific information -- effect on pain, pathophysiology -- and draw conclusions as to the potential of the drug in the prevention of neuropathies during cytostatic treatment", said lead author Jordi Bruna from the varsity.

"This new drug could potentially reach the market soon, since it would be the first available treatment to avoid this type of neuropathy. In addition, it has other medical uses as a non-opioid analgesic."

 Source:https://health.economictimes.indiatimes.com/news/pharma/new-drug-may-prevent-chemotherapy-induced-nerve-damage/61201033

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more